Negative
23Serious
Neutral
Optimistic
Positive
- Total News Sources
- 1
- Left
- 0
- Center
- 0
- Right
- 0
- Unrated
- 1
- Last Updated
- 5 days ago
- Bias Distribution
- 100% Unrated


United Therapeutics Reports Record $799M Revenue, $1B Buyback, Tyvaso DPI Growth
United Therapeutics reported strong financial performance in Q2 2025 with record revenues reaching approximately $798.6 million, marking a 12% year-over-year increase driven by robust sales of key products like Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Despite narrowly missing Wall Street revenue expectations, net income rose significantly to $309.5 million, supported by favorable Medicare changes and strategic pricing. The company authorized a substantial $1 billion share repurchase plan valid through March 2026, signaling confidence in its growth prospects. Analysts maintain an optimistic outlook with average price targets suggesting nearly 25-28% upside and predominantly 'buy' or 'outperform' ratings. United Therapeutics is also advancing its clinical pipeline, with upcoming Phase 3 data from the TETON 2 and ADVANCE OUTCOMES studies expected to fuel future growth. These factors underscore the company's strong commercial foundation, innovation strategy, and effective capital management that position it well for sustained long-term success.
- Total News Sources
- 1
- Left
- 0
- Center
- 0
- Right
- 0
- Unrated
- 1
- Last Updated
- 5 days ago
- Bias Distribution
- 100% Unrated
Negative
23Serious
Neutral
Optimistic
Positive
Stay in the know
Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Gift Subscriptions
The perfect gift for understanding
news from all angles.